Apyx Medical (APYX) Stock News

Apyx Medical Corporation (NASDAQ: APYX) reported third-quarter 2022 results, revealing total revenue of $9.1 million, down 23% year-over-year. Advanced Energy revenue fell 31% to $7.1 million, while OEM revenue rose 34% to $2.0 million. The company recorded a net loss of $5.8 million, worsening from $4.2 million in Q3 2021. Due to ongoing disruptions from an FDA Safety Communication, Apyx revised its 2022 revenue guidance to a range of $44.8 million to $47.9 million, reflecting a potential decline of 8% to 1%. The management emphasized efforts to engage customers and secure new regulatory clearances.

Apyx Medical Corporation (NASDAQ:APYX) will release its third quarter financial results for fiscal year 2022 before the market opens on November 10th. A conference call, scheduled for 8:00 a.m. ET on the same day, will discuss the quarterly results and include a question and answer session. Interested participants can join via phone or listen to a live webcast through the company’s Investor Relations webpage. A replay of the call will be available for two weeks post-event.

Apyx Medical Corporation (NASDAQ: APYX) announced a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology. Leading plastic surgeons, including Dr. Paul Nassif, attest to the device's effectiveness in achieving superior cosmetic results. Renuvion is FDA-cleared for improving lax skin on the neck and for specific dermatological procedures. Hundreds of physicians in the U.S. utilize this innovative technology in their practices, highlighting its safety and efficacy.

Apyx Medical Corporation (NASDAQ:APYX) has announced its participation in the Lake Street Best Ideas Growth Conference on September 14th at The Yale Club, New York, NY. Management will engage in one-on-one meetings, but there will not be a formal presentation. The company specializes in advanced energy technology, offering innovative helium plasma products such as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgeries. These technologies provide controlled heating for optimal surgical results.

Apyx Medical Corporation (NASDAQ: APYX) reported a second quarter 2022 revenue of $10.3 million, an 8% decrease year-over-year. Advanced Energy revenues fell 16% to $8.4 million, while OEM revenues rose 55% to $1.9 million. The net loss increased to $5.4 million from $4.0 million in Q2 2021. The company adjusted its full-year revenue guidance to $51.0 million to $56.4 million, reflecting a 5% to 16% growth expectation. Key 510(k) clearances from the FDA for Renuvion products were achieved, expanding market opportunities.

Apyx Medical Corporation (NASDAQ:APYX) has unveiled its inaugural environmental, social, and governance (ESG) data through a newly released tear sheet. This document, compiled with third-party assistance, highlights the Company's ESG priorities and sets a baseline for future assessments. It includes data for the year ending December 31, 2021, focusing on environmental, social, and governance issues, including energy management, product safety, and Board diversity. CEO Charlie Goodwin emphasized the importance of these efforts to positively impact employees and stakeholders.

Apyx Medical Corporation (NASDAQ: APYX) has received FDA 510(k) clearance for its Renuvion technology, enabling its use in cosmetic procedures aimed at improving lax skin in the neck and chin. Renuvion stands out as the only FDA-cleared solution for this application, providing a minimally-invasive option to address age-related skin sagging. The company anticipates a surge in demand in the cosmetic market, with Renuvion offering effective treatment by directly targeting collagen fibers for a smoother appearance. This development positions Apyx Medical favorably in the growing aesthetic medical field.

Apyx Medical Corporation (NASDAQ:APYX) announced FDA 510(k) clearance for its Renuvion APR Handpiece, allowing use in dermatological procedures for tightening lax skin in the neck and submental areas. This clearance positions Renuvion as the only FDA-cleared device for these applications, targeting an estimated 200,000 neck contouring procedures annually in the U.S. A limited launch is expected by Q3 2022, with full commercialization aimed for year-end. This marks the company's second regulatory clearance within two months, highlighting its commitment to innovative medical solutions.

Apyx Medical Corporation (NASDAQ:APYX) has released positive results from its pivotal Phase II study of the Renuvion device aimed at improving lax skin appearance in the neck and submental area. The study demonstrated key outcomes, with 82.5% of 65 subjects showing improvements at six months, and 96.9% reporting low pain levels post-procedure. Additionally, 85.5% of participants rated their results as improved. No serious adverse events were linked to Renuvion. The company anticipates moving forward with marketing efforts subject to FDA clearance.